Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
104 participants
INTERVENTIONAL
2024-03-07
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
• can a texting platform that integrates symptom triage and prevention education reduce the rate of unnecessary antibiotics for recurrent UTIs as compared to usual care?
Participants enrolled onto the texting platform will:
• receive evidence-based clinical guidance for the management of symptoms of UTI and receive educational videos on how to prevent UTIs. An important secondary outcome is to determine if the texting platform improves self-efficacy for the management of recurrent UTI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative, Controlled Study to Evaluate the Clinical Accuracy of the Velieve U.S. UTI Urine Analysis Test System
NCT04371159
Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers
NCT00731315
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04020341
The INSPIRE-ASP UTI Trial
NCT03697096
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
NCT06808451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Electronic health record (EHR)-integrated texting platform
Patients will be enrolled into a texting platform for the management of recurrent UTI.
EHR-integrated texting platform (Urotrust)
* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI
* Evidence-based prevention education material on recurrent UTIs
* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment
* Standard-of-care management for recurrent UTI
Usual care
Patients will receive usual care through their providers.
Usual care
• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EHR-integrated texting platform (Urotrust)
* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI
* Evidence-based prevention education material on recurrent UTIs
* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment
* Standard-of-care management for recurrent UTI
Usual care
• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Females who currently meet the criteria for recurrent UTIs
4. Age 18 years or older
5. Owns a mobile device with text messaging capability
6. Ability to read and write English
7. Currently receiving care from a provider in Penn Urogynecology or Penn Urology
Exclusion Criteria
2. History of interstitial cystitis/bladder pain syndrome or current diagnosis of chronic pelvic pain
3. On continuous suppressive antibiotics currently
4. Currently pregnant or within 6 weeks of pregnancy
5. Transplant patient on immunosuppressive medication currently
6. Practice of chronic self-catheterization
18 Years
100 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Independence Blue Cross
OTHER
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lily Arya
Professor of OBGYN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arya LA, Agrawal S, Ikpeama N, Harvie H, Feldman RH, Dutcher L. Implementing a Digital Platform for Recurrent Urinary Tract Infections. Urogynecology (Phila). 2025 Mar 1;31(3):183-193. doi: 10.1097/SPV.0000000000001604. Epub 2024 Nov 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
853917
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.